Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.15 EUR | +0.38% | +2.16% | +43.65% |
04-18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
03-07 | Van Lanschot Kempen Plans Early Redemption of EUR100 Million Notes | MT |
Strengths
- The group's high margin levels account for strong profits.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+43.65% | 1.85B | - | ||
+7.52% | 8.98B | B+ | ||
+10.85% | 3.42B | C- | ||
-30.16% | 3.31B | B | ||
+13.32% | 2.53B | B- | ||
+17.25% | 2.45B | C | ||
+45.87% | 2.22B | - | - | |
+29.12% | 1.72B | B+ | ||
+6.20% | 1.4B | B | ||
-19.47% | 930M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VLK Stock
- VA3 Stock
- Ratings Van Lanschot Kempen N.V